The recently discovered functions of γtubulin in the nucleus and their inverse correlation with the tumor suppressor RB1, together with the high expression of γtubulin in proliferating cells suggest that drugs specifically designed to inhibit the nuclear activity of γtubulin may pave the way for chemotherapies that target a broad range of malignant tumors but have no impact on healthy cells. This evidence concerns the gene RB1 and cancer.